# Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

> **NCT04322890** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 6000 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation
- ALK Gene Mutation
- ROS1 Gene Mutation
- MET Gene Mutation

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Alectinib 150 MG
- **DRUG:** Crizotinib 250 MG
- **DRUG:** Savolitinib, Crizotinib.
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04322890
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-16
- **Primary completion:** 2026-12-24
- **Final completion:** 2027-12-24
- **Target enrollment:** 6000 (ESTIMATED)
- **Last updated:** 2024-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322890, "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04322890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*